ACM
MRNA icon

Arlington Capital Management’s Moderna MRNA Stock Holding History

Arlington Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,958
Closed -$233K – 96
2024
Q2 		$233K Sell
1,958
-92
-4% -$11.6K 0.2% 64
2024
Q1 		$218K Hold
2,050
– – 0.18% 78
2023
Q4 		$204K Sell
2,050
-65
-3% -$5.47K 0.19% 90
2023
Q3 		$218K Buy
+2,115
New +$236K 0.23% 58

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Arlington Capital Management's MRNA Position: Q3 2024 in Review

Arlington Capital Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,958 shares — an estimated $233K sold.

Arlington Capital Management first reported a position in MRNA in Q3 2023 and held it in 4 quarters. The position peaked at $233K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Arlington Capital Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Arlington Capital Management sold 1,958 Moderna shares in Q3 2024, an estimated $233K.
  • Arlington Capital Management first reported a position in Moderna in Q3 2023 and held it in 4 quarters.
  • Arlington Capital Management's Moderna position peaked at $233K in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Arlington Capital Management's 13F filing for Q3 2024, filed 30 Oct 2024.